fluoxetine has been researched along with Alzheimer Disease in 52 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clomipramine appeared much more effective and better tolerated than fluoxetine in this very old patient despite its potential anticholinergic effect and the coexistence of Alzheimer disease." | 7.70 | Treatment of obsessive-compulsive disorder using clomipramine in a very old patient. ( Trappler, B, 1999) |
| " TRAZODONE: Studies conducted in patients with Alzheimer's disease, mixed type dementia, or fronto-temporal dementia have shown the efficacy of trazodone for diverse types of symptoms: sadness, emotional disorders, irritability, fear, psychomotor instability, delirant ideas." | 4.82 | [Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias]. ( Lebert, F, 2003) |
| "Clomipramine appeared much more effective and better tolerated than fluoxetine in this very old patient despite its potential anticholinergic effect and the coexistence of Alzheimer disease." | 3.70 | Treatment of obsessive-compulsive disorder using clomipramine in a very old patient. ( Trappler, B, 1999) |
| "Fluoxetine treatment for depression in AD did not differ significantly from treatment with placebo." | 2.70 | A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. ( Chemerinski, E; Petracca, GM; Starkstein, SE, 2001) |
| "Fluoxetine treatment showed protective effect against SI, AD and prevents exacerbation of CVD." | 1.72 | Fluoxetine ameliorates Alzheimer's disease progression and prevents the exacerbation of cardiovascular dysfunction of socially isolated depressed rats through activation of Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome signaling pathway. ( Aboutaleb, AS; Abu-Elfotuh, K; Al-Najjar, AH; Badawi, GA; Mohammed, AA, 2022) |
| "The prevalence of Alzheimer's disease (AD) has been a major health concern for a long time." | 1.72 | Unraveling the Binding Mechanism of Alzheimer's Drugs with Irisin: Spectroscopic, Calorimetric, and Computational Approaches. ( Hassan, MI; Islam, A; Kazim, SN; Khan, T; Shahid, M; Shamsi, A; Waseem, R, 2022) |
| "For the potential therapy of Alzheimer's disease (AD), cholinesterases (ChE) and monoamine oxidase (MAO) are key enzymes that regulate the level of acetylcholinesterase (AChE)/butyrylcholinesterase (BChE) and monoamines." | 1.62 | Fluoxetine and sertraline based multitarget inhibitors of cholinesterases and monoamine oxidase-A/B for the treatment of Alzheimer's disease: Synthesis, pharmacology and molecular modeling studies. ( Khan, JA; Nadeem, MS; Rashid, U, 2021) |
| "Fluoxetine (FLX) has been shown to improve cognition in the early stage of AD and to be associated with diminishing synapse degeneration in the hippocampus." | 1.56 | Fluoxetine Protects against Dendritic Spine Loss in Middle-aged APPswe/PSEN1dE9 Double Transgenic Alzheimer's Disease Mice. ( Gao, Y; Huang, W; Ma, J; Tang, W; Tang, Y, 2020) |
| "Treatment of Alzheimer's disease (AD) patients with the antidepressant fluoxetine is known to improve memory and cognitive function." | 1.43 | Fluoxetine Treatment Induces Seizure Behavior and Premature Death in APPswe/PS1dE9 Mice. ( de Nijs, L; Hoogland, G; Prickaerts, J; Rutten, BP; Sierksma, AS; Steinbusch, HW; van den Hove, DL; van Leeuwen, FW; Vanmierlo, T, 2016) |
| "Treatment with fluoxetine for 6 months resulted in significant symptom relief and an increasing density of serotonin transporter sites when compared to the beginning of treatment." | 1.32 | Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites. ( Bodner, T; Donnemiller, E; Gurka, P; Marksteiner, J; Walch, T, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (26.92) | 18.2507 |
| 2000's | 10 (19.23) | 29.6817 |
| 2010's | 20 (38.46) | 24.3611 |
| 2020's | 8 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| McKenna, MT | 1 |
| Proctor, GR | 1 |
| Young, LC | 1 |
| Harvey, AL | 1 |
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Minarini, A | 1 |
| Rosini, M | 1 |
| Tumiatti, V | 1 |
| Recanatini, M | 1 |
| Melchiorre, C | 1 |
| Nadeem, MS | 1 |
| Khan, JA | 1 |
| Rashid, U | 1 |
| Abu-Elfotuh, K | 2 |
| Ragab, GM | 1 |
| Salahuddin, A | 1 |
| Jamil, L | 1 |
| Abd Al Haleem, EN | 1 |
| Al-Najjar, AH | 1 |
| Mohammed, AA | 1 |
| Aboutaleb, AS | 1 |
| Badawi, GA | 1 |
| Waseem, R | 1 |
| Shamsi, A | 1 |
| Khan, T | 1 |
| Hassan, MI | 1 |
| Kazim, SN | 1 |
| Shahid, M | 1 |
| Islam, A | 1 |
| Hill, MA | 1 |
| Gammie, SC | 1 |
| Ma, J | 2 |
| Gao, Y | 2 |
| Tang, W | 2 |
| Huang, W | 2 |
| Tang, Y | 3 |
| Sharma, A | 1 |
| Mohammad, A | 1 |
| Saini, AK | 1 |
| Goyal, R | 1 |
| Sierra-Fonseca, JA | 1 |
| Rodriguez, M | 1 |
| Themann, A | 1 |
| Lira, O | 1 |
| Flores-Ramirez, FJ | 1 |
| Vargas-Medrano, J | 1 |
| Gadad, BS | 1 |
| Iñiguez, SD | 1 |
| Jiang, L | 2 |
| Chao, FL | 2 |
| Zhou, CN | 2 |
| Zhang, L | 2 |
| Huang, CX | 1 |
| Zhang, Y | 4 |
| Luo, YM | 1 |
| Xiao, Q | 1 |
| Yu, HR | 1 |
| Jiang, R | 1 |
| Sun, DS | 2 |
| Gao, LF | 2 |
| Jin, L | 2 |
| Wu, H | 2 |
| Wang, Q | 2 |
| Zhou, Y | 1 |
| Fan, S | 1 |
| Jiang, X | 1 |
| Ke, D | 2 |
| Lei, H | 2 |
| Wang, JZ | 2 |
| Liu, GP | 2 |
| Fan, JH | 1 |
| Wu, YX | 1 |
| Dou, XY | 1 |
| Marlatt, MW | 1 |
| Potter, MC | 1 |
| Bayer, TA | 1 |
| van Praag, H | 1 |
| Lucassen, PJ | 1 |
| Epelbaum, S | 1 |
| Dubois, B | 2 |
| Zhu, L | 1 |
| Ploessl, K | 1 |
| Kung, HF | 1 |
| Yang, C | 1 |
| Guo, X | 1 |
| Wang, GH | 1 |
| Wang, HL | 1 |
| Liu, ZC | 1 |
| Liu, H | 1 |
| Zhu, ZX | 1 |
| Li, Y | 1 |
| Wang, J | 2 |
| Xu, H | 2 |
| Zhu, S | 2 |
| Wang, H | 2 |
| He, J | 1 |
| Zhang, H | 1 |
| Guo, H | 2 |
| Kong, J | 2 |
| Huang, Q | 2 |
| Li, XM | 2 |
| Chew, AP | 1 |
| Lim, WS | 1 |
| Tan, KT | 1 |
| Stagni, F | 1 |
| Giacomini, A | 1 |
| Guidi, S | 1 |
| Ciani, E | 1 |
| Ragazzi, E | 1 |
| Filonzi, M | 1 |
| De Iasio, R | 1 |
| Rimondini, R | 1 |
| Bartesaghi, R | 1 |
| Qiao, J | 1 |
| Adilijiang, A | 1 |
| Zhang, R | 1 |
| Guo, W | 1 |
| Luo, G | 1 |
| Qiu, Y | 1 |
| Yun, HM | 1 |
| Park, KR | 1 |
| Kim, EC | 1 |
| Kim, S | 3 |
| Hong, JT | 1 |
| Sierksma, AS | 1 |
| de Nijs, L | 1 |
| Hoogland, G | 1 |
| Vanmierlo, T | 1 |
| van Leeuwen, FW | 1 |
| Rutten, BP | 1 |
| Steinbusch, HW | 1 |
| Prickaerts, J | 1 |
| van den Hove, DL | 1 |
| Zhou, L | 1 |
| Ma, SL | 1 |
| Yeung, PK | 1 |
| Wong, YH | 1 |
| Tsim, KW | 1 |
| So, KF | 1 |
| Lam, LC | 1 |
| Chung, SK | 1 |
| Xia, M | 1 |
| Yang, L | 1 |
| Sun, G | 1 |
| Qi, S | 1 |
| Li, B | 1 |
| Rozzini, L | 1 |
| Chilovi, BV | 1 |
| Conti, M | 1 |
| Bertoletti, E | 1 |
| Zanetti, M | 1 |
| Trabucchi, M | 1 |
| Padovani, A | 1 |
| McMillan, PJ | 1 |
| White, SS | 2 |
| Franklin, A | 1 |
| Greenup, JL | 2 |
| Leverenz, JB | 2 |
| Raskind, MA | 2 |
| Szot, P | 2 |
| Chang, KA | 1 |
| Kim, JA | 1 |
| Joo, Y | 1 |
| Shin, KY | 1 |
| Kim, HS | 1 |
| Suh, YH | 1 |
| Ledo, JH | 1 |
| Azevedo, EP | 1 |
| Clarke, JR | 1 |
| Ribeiro, FC | 1 |
| Figueiredo, CP | 1 |
| Foguel, D | 1 |
| De Felice, FG | 1 |
| Ferreira, ST | 1 |
| Lebert, F | 2 |
| Marksteiner, J | 1 |
| Walch, T | 1 |
| Bodner, T | 1 |
| Gurka, P | 1 |
| Donnemiller, E | 1 |
| Peskind, ER | 1 |
| Manev, R | 1 |
| Manev, H | 1 |
| Le Ber, I | 1 |
| Mowla, A | 1 |
| Mosavinasab, M | 1 |
| Haghshenas, H | 1 |
| Borhani Haghighi, A | 1 |
| Geldmacher, DS | 1 |
| Waldman, AJ | 1 |
| Doty, L | 1 |
| Heilman, KM | 1 |
| Tejani-Butt, SM | 1 |
| Yang, J | 1 |
| Zaffar, H | 1 |
| Pasquier, F | 1 |
| Goudemand, M | 1 |
| Petit, H | 1 |
| Omar, SJ | 1 |
| Robinson, D | 1 |
| Davies, HD | 1 |
| Miller, TP | 1 |
| Tinklenberg, JR | 1 |
| Reynolds, CF | 1 |
| Auer, SR | 1 |
| Monteiro, IM | 1 |
| Reisberg, B | 1 |
| Oakley, F | 1 |
| Sunderland, T | 1 |
| Anderson, J | 1 |
| Compton, SA | 1 |
| Auchus, AP | 1 |
| Bissey-Black, C | 1 |
| Trappler, B | 2 |
| Cohen, CI | 1 |
| Petracca, GM | 1 |
| Chemerinski, E | 1 |
| Starkstein, SE | 1 |
| Sobow, TM | 1 |
| Maczkiewicz, M | 1 |
| Kloszewska, I | 1 |
| González Moneo, MJ | 1 |
| Garrido Barral, A | 1 |
| Hawkins, JW | 1 |
| Odenheimer, GL | 1 |
8 reviews available for fluoxetine and Alzheimer Disease
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium | 2008 |
Alzheimer's disease large-scale gene expression portrait identifies exercise as the top theoretical treatment.
Topics: Alzheimer Disease; Curcumin; Female; Fluoxetine; Gene Expression; Humans; Inositol; Interferons; Mal | 2022 |
[Subjective cognitive complaint. From anxiety to prodromal Alzheimer's disease?].
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cognition Diso | 2013 |
[Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias].
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Tri | 2003 |
[Frontotemporal dementia].
Topics: Adenosine Triphosphatases; Aged; Aged, 80 and over; Alzheimer Disease; Amyotrophic Lateral Sclerosis | 2007 |
Depression: making the diagnosis and using SSRIs in the older patient.
Topics: 1-Naphthylamine; Adult; Aged; Alzheimer Disease; Depressive Disorder; Diagnosis, Differential; Dose- | 1996 |
[Latest therapies for treating dementia].
Topics: Adult; Aged; Alzheimer Disease; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepress | 2002 |
Management of patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Causality; Desipramine; Electroco | 1991 |
7 trials available for fluoxetine and Alzheimer Disease
| Article | Year |
|---|---|
Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amygdala; Animals; Behavior, Animal; Cerebral Cortex; Cerebrum; Combined Modality | 2013 |
Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholin | 2007 |
Behavioral symptoms in dementia: community-based research.
Topics: Aged; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Dementia; Double-Blind Method; Femal | 1996 |
Assessment of motor and process skills as a measure of IADL functioning in pharmacologic studies of people with Alzheimer's disease: a pilot study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cross-Over Studies; Double-Blind Method; Drug T | 1997 |
Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Double-Blin | 1997 |
Use of SSRIs in "very old" depressed nursing home residents.
Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Alzheimer Disease; Central Nervous System Diseases; Dement | 1998 |
A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Antidepressive Agents, Second-Generation; Depressive | 2001 |
37 other studies available for fluoxetine and Alzheimer Disease
| Article | Year |
|---|---|
Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Magnetic Resonance Spect | 1997 |
Fluoxetine and sertraline based multitarget inhibitors of cholinesterases and monoamine oxidase-A/B for the treatment of Alzheimer's disease: Synthesis, pharmacology and molecular modeling studies.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Drug Design; Fluoxetine; Humans; Mice; Monoam | 2021 |
Attenuative Effects of Fluoxetine and
Topics: Aluminum Chloride; Alzheimer Disease; Animals; Fluoxetine; Kidney; Liver; Male; Neuroprotective Agen | 2021 |
Fluoxetine ameliorates Alzheimer's disease progression and prevents the exacerbation of cardiovascular dysfunction of socially isolated depressed rats through activation of Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome signaling pathway.
Topics: Alzheimer Disease; Animals; Antidepressive Agents; Antioxidants; Behavior, Animal; Biogenic Monoamin | 2022 |
Unraveling the Binding Mechanism of Alzheimer's Drugs with Irisin: Spectroscopic, Calorimetric, and Computational Approaches.
Topics: Alzheimer Disease; Binding Sites; Calorimetry; Fibronectins; Fluoxetine; Humans; Molecular Docking S | 2022 |
Fluoxetine Protects against Dendritic Spine Loss in Middle-aged APPswe/PSEN1dE9 Double Transgenic Alzheimer's Disease Mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Dendritic Spines; Disease Models, Animal | 2020 |
Neuroprotective Effects of Fluoxetine on Molecular Markers of Circadian Rhythm, Cognitive Deficits, Oxidative Damage, and Biomarkers of Alzheimer's Disease-Like Pathology Induced under Chronic Constant Light Regime in Wistar Rats.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Biom | 2021 |
Autophagy Induction and Accumulation of Phosphorylated Tau in the Hippocampus and Prefrontal Cortex of Adult C57BL/6 Mice Subjected to Adolescent Fluoxetine Treatment.
Topics: Adolescent; Alzheimer Disease; Animals; Antidepressive Agents, Second-Generation; Autophagy; Brain; | 2021 |
Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; beta Catenin; CA1 | 2017 |
Fluoxetine administration during adolescence attenuates cognitive and synaptic deficits in adult 3×TgAD mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Brain-Derived Neurotrophic Factor; Cyclic | 2017 |
Fluoxetine delays the cognitive function decline and synaptic changes in a transgenic mouse model of early Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Dendritic Spines; Disease Models, Animal; Fluoxet | 2019 |
Chemistry. Expanding the scope of fluorine tags for PET imaging.
Topics: Alzheimer Disease; Aniline Compounds; Celecoxib; Ethylene Glycols; Fluorescent Dyes; Fluorine Radioi | 2013 |
Changes in tau phosphorylation levels in the hippocampus and frontal cortex following chronic stress.
Topics: Alzheimer Disease; Analysis of Variance; Anhedonia; Animals; Antidepressive Agents, Second-Generatio | 2014 |
Fluoxetine improves behavioral performance by suppressing the production of soluble β-amyloid in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Disease Models, Animal; Emotions; | 2014 |
Donepezil-induced hepatotoxicity in an elderly adult taking fluoxetine.
Topics: Aged; Alanine Transaminase; Alzheimer Disease; Antidepressive Agents, Second-Generation; Aspartate A | 2014 |
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
Topics: Alzheimer Disease; Animals; Animals, Newborn; Cognition; Dendrites; Disease Models, Animal; Down Syn | 2015 |
Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Astrocytes; Brain | 2016 |
Serotonin 6 receptor controls Alzheimer's disease and depression.
Topics: Adaptor Proteins, Signal Transducing; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid Pre | 2015 |
Fluoxetine Treatment Induces Seizure Behavior and Premature Death in APPswe/PS1dE9 Mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anticonvulsants; Body Weight; Disease Mo | 2016 |
Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents; Brain-Derived Neurotrophic | 2017 |
Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Animals; Anxiety; Asian People; Behavior, Animal | 2016 |
Mechanism of depression as a risk factor in the development of Alzheimer's disease: the function of AQP4 and the glymphatic system.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anhedonia; Animals; Antidepressive Agents; Aquaporin 4; Br | 2017 |
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depr | 2010 |
Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Binding Sites; Cell Count; Dopamine beta-Hydroxylase; Fe | 2011 |
Therapeutic potentials of neural stem cells treated with fluoxetine in Alzheimer's disease.
Topics: Alzheimer Disease; Fluoxetine; Humans; Neural Stem Cells; Selective Serotonin Reuptake Inhibitors | 2012 |
Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anhedonia; Animals; Brain Chemistry; Cognition Disorders; | 2013 |
Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Binding Sites; Brain; Carrier Proteins; Female; Fluoxeti | 2003 |
Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Dendrites; Female; | 2006 |
Could treatment with arundic acid (ONO-2506) increase vulnerability for depression?
Topics: Alzheimer Disease; Animals; Caprylates; Clinical Trials as Topic; Comorbidity; Depression; Disease M | 2006 |
Fluoxetine in dementia of the Alzheimer's type: prominent adverse effects and failure to improve cognition.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Female; Fluoxetine; Humans; Male; Psychiatric Status R | 1994 |
Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Autoradiography; Carrier Proteins; Female; Fluoxetine; H | 1993 |
Euphoria with buspirone after fluoxetine treatment.
Topics: Aged; Alzheimer Disease; Anxiety Disorders; Buspirone; Euphoria; Female; Fluoxetine; Humans; Male | 1993 |
Fluoxetine and visual hallucinations in dementia.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Dementia; Depressive Disorder; Dr | 1995 |
Fluoxetine induced bradycardia in presenile dementia.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Bradycardia; Dementia; Fluoxetine | 1997 |
Treatment of obsessive-compulsive disorder using clomipramine in a very old patient.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; B | 1999 |
Tianeptine versus fluoxetine in the treatment of depression complicating Alzheimer's disease.
Topics: Alzheimer Disease; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depre | 2001 |
Nonsedating treatments for Alzheimer's patients with behavioral problems.
Topics: Alzheimer Disease; Buspirone; Fluoxetine; Humans; Selegiline; Sleep; Trazodone | 1992 |